Medical Condition News

RSS

Study: Emerging pharmaceutical platform may produce undesirable effects on eye function

According to new research by University of Kentucky investigators, an emerging pharmaceutical platform used in treating a variety of diseases may produce unintended and undesirable effects on eye function.

12 Oct 2011

UB scientists discover promising new drug target for Alzheimer's

A tiny piece of a critical receptor that fuels the brain and without which sentient beings cannot live has been discovered by University at Buffalo scientists as a promising new drug target for Alzheimer's and other neurodegenerative diseases.

12 Oct 2011

UPC develops active knee-ankle orthosis to assist gait in people with incomplete SCI

A team from the Department of Mechanical Engineering and the Biomedical Engineering Research Centre (CREB) of the Universitat Politècnica de Catalunya. BarcelonaTech (UPC) has developed an active knee-ankle orthosis to assist gait in people with incomplete spinal cord injury. The project is being carried out in collaboration with the University of A Coruña and the University of Extremadura.

12 Oct 2011

COPAXONE reduces loss of brain volume in patients with RRMS

Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.

12 Oct 2011

New robust technique holds promise for identifying trace mutant DNA sequences

Molecular DNA testing methods offer clinicians powerful tools that serve to confirm or identify disease diagnoses. High sensitivity and high specificity, however, are frequently a challenge to achieve with these methods. In a study scheduled for publication in the November issue of The Journal of Molecular Diagnostics, researchers describe a new, robust technique that holds promise for identifying trace mutant DNA sequences in an overwhelming population of unmutated DNA.

12 Oct 2011

PROLOR receives U.S. patent allowance for CTP-modified interferons

PROLOR Biotech, Inc. today announced that it received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering PROLOR's CTP-modified interferons.

12 Oct 2011

Phyllodes tumors more prevalent among Hispanic women

According to a study published in the October issue of the Journal of the American College of Surgeons, phyllodes tumors - rare breast malignancies accounting for 0.5 to one percent of all breast tumors - tend to be more prevalent in Hispanic patients.

12 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the initiation of its first clinical trial to evaluate the Safety and Efficacy of PAZ320 when added to oral agents or Insulin regimen in Patients with Type 2 Diabetes Mellitus.

12 Oct 2011

NovaSom enters unique agreement with HealthAmerica to treat sleep disorders

NovaSom, Inc., the market leader in technology-driven, payer-aligned cost-saving solutions for obstructive sleep apnea (OSA) management, today announced it has entered a preferred relationship to aid HealthAmerica with managing its sleep disorder diagnostic expenses.

11 Oct 2011

Aquaporin AQP10 retains transport ability even when carbohydrate structure is removed

Water channels exist not only in nature - microscopical water channels are also present in the cells of the body, where they ensure that water can be transported through the protective surface of the cell. Scientists at the University of Gothenburg, Sweden, have discovered that one type of the body's water channels can be modified such that it becomes more stable, which may be significant in the treatment of several diseases.

11 Oct 2011

Patients with poorly controlled diabetes may benefit from behavioral, educational interventions

Three randomized controlled trials published Online First today in Archives of Internal Medicine examine the effectiveness of behavioral and educational interventions for patients with poorly controlled diabetes.

11 Oct 2011

Receptor tyrosine kinases control PI3K signaling in human KRAS mutant colorectal cancers

Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers - combine them with inhibitors of the MEK/ERK signaling pathway.

11 Oct 2011

Tantalizing glimmers about roles of CCR2 gene, Th17 cell and a missing monocyte

An estimated 1.3 million people in the United States suffer from rheumatoid arthritis. The causes behind this chronic disease — which can exhibit itself as pain, swelling, stiffness, deformation, and loss of function in the joints — have eluded scientists for centuries. A new study by UNC researchers offers tantalizing glimmers about the roles of a gene called CCR2, an immune system cell called Th17 cell, and a missing monocyte.

11 Oct 2011

Aspirin desensitization procedure can benefit patients with sinusitis, asthma and AERD

Beth Moore can now keep up with her children. The suburban Philadelphia mother of two had suffered from allergies and chronic sinusitis since her teens. With age her symptoms became more severe, turning into bronchitis and eventually asthma, diminishing her ability to breathe and sapping her of her energy. The only complete relief came from aspirin; and the aspirin desensitization that allowed her to overcome her aspirin allergy and end her decades-long battle with sinusitis.

11 Oct 2011

Omeros initiates OMS302 Phase 3 trial in intra-ocular lens replacement surgery

Omeros Corporation today announced that the first patients have been treated in the Company's Phase 3 clinical program evaluating OMS302 in intra-ocular lens replacement surgery.

11 Oct 2011

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

DARA BioSciences, Inc. today announced the Journal of Pain and Symptom Management, an internationally respected, peer-reviewed journal, has published results of a Phase II safety and efficacy study of KRN5500 for the treatment of neuropathic pain in patients with cancer.

11 Oct 2011

World class scientist presents fourth Environmental Microbiology Lecture

World class scientist Professor Willem M. de Vos will explain next Monday how the microbes that are closest to our hearts - gut microbes - could underpin a new way of thinking about human biology. As well as looking at our own genes, we can now include those of our microbes in studies of human health and disease. This is a significant shift in the way we approach human biology.

11 Oct 2011

Many cancer survivors continue to have poorer health years after completion of treatment

Forty-five per cent of cancer survivors in Northern Ireland suffer from physical and mental health problems years after their treatment has finished, according to new research from Macmillan Cancer Support and Queen's University Belfast.

11 Oct 2011

New mechanism to enhance restoration of blood flow in ischemic diseases

In Nature, VIB-K.U.Leuven researchers describe a new mechanism to enhance the restoration of the blood flow in ischemic diseases, which are among the leading causes of death worldwide.

11 Oct 2011